Swetha Prabhakaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Swetha Prabhakaran has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Joseph Cherng Kong
Department of Colorectal Surgery Alfred Hospital Melbourne Victoria Australia
21 shared publications - Alexander Graham Heriot
Peter MacCallum Cancer Centre Melbourne Victoria Australia
7 shared publications Satish K. Warrier
Department of Colorectal Surgery, Alfred Hospital, Melbourne, Australia
6 shared publications- Stephen Bell
Department of Colorectal Surgery Cabrini Health Melbourne Victoria Australia
6 shared publications Chip Farmer
Department of Colorectal Surgery Alfred Health Melbourne Victoria Australia
5 shared publicationsPeter Carne
Department of Colorectal Surgery Alfred Hospital Melbourne Victoria Australia
5 shared publications
Latest Publications
- 13 October 2026
- Published by Wiley in Anz Journal of Surgery
Platelet‐Rich Plasma ( PRP ) for Pilonidal Sinus Disease: An Updated Systematic Review and Meta‐Analysis
Background: Platelet‐rich plasma (PRP) has been utilised in wound healing in pilonidal sinus disease (PSD). This study aims to perform an updated systematic review and meta‐analysis on the utility of PRP in PSD. Methods: This study was undertaken in accordance with the PRISMA guidelines. PubMed, EMBASE and Medline databases were last searched on 22 February 2026 following PROSPERO Registration (ID CRD420251246388). Any comparative study investigating the role of PRP in facilitating wound healing in patients with PSD was included. Systematic reviews, meta‐analyses, case reports and conference proceedings were excluded. A Newcastle–Ottawa score and a GRADE assessment were performed. Results: Fourteen studies met the inclusion criteria. A total of 1346 patients were included in this study with 647 in the PRP group and 699 in the control group. There was heterogeneity in PRP administration. Pooled analysis demonstrated a statistically significant reduction in healing time ( p < 0.01), as well as in return‐to‐work time ( p < 0.01) with PRP application. Pooled analysis also demonstrated a significant reduction in pain severity with PRP application ( p < 0.01) as well as a significantly lower recurrence rate ( p = 0.03). No significant differences were noted between the two groups with regards to return to activities of daily living or complication rates. Conclusion: The use of PRP as an adjunct in the management of PSD has been shown to significantly reduce wound healing time, pain severity, time to return to work and post‐operative recurrence rate. Further research is required to determine an optimal protocol.
- 13 October 2026
- Published by Wiley in Anz Journal of Surgery
Platelet‐Rich Plasma ( PRP ) for Pilonidal Sinus Disease: An Updated Systematic Review and Meta‐Analysis
Background: Platelet‐rich plasma (PRP) has been utilised in wound healing in pilonidal sinus disease (PSD). This study aims to perform an updated systematic review and meta‐analysis on the utility of PRP in PSD. Methods: This study was undertaken in accordance with the PRISMA guidelines. PubMed, EMBASE and Medline databases were last searched on 22 February 2026 following PROSPERO Registration (ID CRD420251246388). Any comparative study investigating the role of PRP in facilitating wound healing in patients with PSD was included. Systematic reviews, meta‐analyses, case reports and conference proceedings were excluded. A Newcastle–Ottawa score and a GRADE assessment were performed. Results: Fourteen studies met the inclusion criteria. A total of 1346 patients were included in this study with 647 in the PRP group and 699 in the control group. There was heterogeneity in PRP administration. Pooled analysis demonstrated a statistically significant reduction in healing time ( p < 0.01), as well as in return‐to‐work time ( p < 0.01) with PRP application. Pooled analysis also demonstrated a significant reduction in pain severity with PRP application ( p < 0.01) as well as a significantly lower recurrence rate ( p = 0.03). No significant differences were noted between the two groups with regards to return to activities of daily living or complication rates. Conclusion: The use of PRP as an adjunct in the management of PSD has been shown to significantly reduce wound healing time, pain severity, time to return to work and post‐operative recurrence rate. Further research is required to determine an optimal protocol.
- Top Cited PapersOpen Access
- 7 March 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (5) , 111741
The utility of large language models in oncological multidisciplinary team meetings: A systematic review
- 7 March 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (5) , 111741
Top Cited PapersOpen AccessThe utility of large language models in oncological multidisciplinary team meetings: A systematic review
- 5 March 2026
- Published by Wiley in Anz Journal of Surgery
Robot‐Assisted Emergency Colorectal Surgery in Australia: The Time Is Now
- 5 March 2026
- Published by Wiley in Anz Journal of Surgery
Robot‐Assisted Emergency Colorectal Surgery in Australia: The Time Is Now
- 7 February 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (3) , 619-625
Neoadjuvant Glucagon‐Like Peptide‐1 Receptor Agonists in Abdominal Wall Hernia Surgery: A Narrative Review
Purpose: Glucagon‐like peptide‐1 (GLP‐1) receptor agonist medications are revolutionizing approaches to weight loss, including in the neoadjuvant setting. Obesity poses a challenge to the hernia surgeon, as an independent modifiable risk factor for hernia occurrence which also connotates a higher risk of post‐operative morbidity, complications, and recurrence. This is the first review to investigate the neoadjuvant potential of GLP‐1 receptor agonists to result in weight loss prior to elective abdominal wall hernia surgery in obese patients. Methods: A computer‐assisted search of Medline, PubMed, and EMBASE was conducted to identify studies reporting on the utility of GLP‐1 receptor agonist medications in neoadjuvant weight loss prior to abdominal wall hernia surgery. Results: A total of three retrospective studies were included in this narrative study. In this study, GLP‐1 receptor agonists have been found to contribute to either statistically significantly greater weight loss and BMI reductions, or at least equivalent outcomes, in the pre‐operative setting prior to elective abdominal wall hernia repair, when compared to conventional lifestyle modifications alone. However, neoadjuvant GLP‐1 receptor agonists have not been shown to be superior to pre‐operative bariatric surgery in effecting weight loss and BMI reduction. GLP‐1 receptor agonists have also been found to be associated with an earlier surgery date if weight loss is the barrier to surgery, when compared to both lifestyle modifications and bariatric surgery. Crucially, GLP‐1 receptor agonists have not been shown to lead to more complications or hernia recurrences in terms of post‐operative outcomes. These results are limited by the relative paucity of data, the heterogeneity of the included studies, and the absence of long‐term outcomes. Conclusion: There may be a promising role for GLP‐1 receptor agonists in the neoadjuvant approach to abdominal wall hernia repair, by inducing and accelerating pre‐operative weight loss without a negative impact on post‐operative outcomes. Only limited conclusions can yet be drawn at this stage and large‐scale prospective studies, ideally in a randomized controlled setting, are necessary to investigate this finding further.
- 7 February 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (3) , 619-625
Neoadjuvant Glucagon‐Like Peptide‐1 Receptor Agonists in Abdominal Wall Hernia Surgery: A Narrative Review
Purpose: Glucagon‐like peptide‐1 (GLP‐1) receptor agonist medications are revolutionizing approaches to weight loss, including in the neoadjuvant setting. Obesity poses a challenge to the hernia surgeon, as an independent modifiable risk factor for hernia occurrence which also connotates a higher risk of post‐operative morbidity, complications, and recurrence. This is the first review to investigate the neoadjuvant potential of GLP‐1 receptor agonists to result in weight loss prior to elective abdominal wall hernia surgery in obese patients. Methods: A computer‐assisted search of Medline, PubMed, and EMBASE was conducted to identify studies reporting on the utility of GLP‐1 receptor agonist medications in neoadjuvant weight loss prior to abdominal wall hernia surgery. Results: A total of three retrospective studies were included in this narrative study. In this study, GLP‐1 receptor agonists have been found to contribute to either statistically significantly greater weight loss and BMI reductions, or at least equivalent outcomes, in the pre‐operative setting prior to elective abdominal wall hernia repair, when compared to conventional lifestyle modifications alone. However, neoadjuvant GLP‐1 receptor agonists have not been shown to be superior to pre‐operative bariatric surgery in effecting weight loss and BMI reduction. GLP‐1 receptor agonists have also been found to be associated with an earlier surgery date if weight loss is the barrier to surgery, when compared to both lifestyle modifications and bariatric surgery. Crucially, GLP‐1 receptor agonists have not been shown to lead to more complications or hernia recurrences in terms of post‐operative outcomes. These results are limited by the relative paucity of data, the heterogeneity of the included studies, and the absence of long‐term outcomes. Conclusion: There may be a promising role for GLP‐1 receptor agonists in the neoadjuvant approach to abdominal wall hernia repair, by inducing and accelerating pre‐operative weight loss without a negative impact on post‐operative outcomes. Only limited conclusions can yet be drawn at this stage and large‐scale prospective studies, ideally in a randomized controlled setting, are necessary to investigate this finding further.
- 18 August 2023
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 408 (1) , 1-11
Accuracy of deep neural learning models in the imaging prediction of pathological complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review
Purpose Up to 15–27% of patients achieve pathologic complete response (pCR) following neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). Deep neural learning (DL) algorithms have been suggested to be a useful adjunct to allow accurate prediction of pCR and to identify patients who could potentially avoid surgery. This systematic review aims to interrogate the accuracy of DL algorithms at predicting pCR. Methods Embase (PubMed, MEDLINE) databases and Google Scholar were searched to identify eligible English-language studies, with the search concluding in July 2022. Studies reporting on the accuracy of DL models in predicting pCR were selected for review and information pertaining to study characteristics and diagnostic measures was extracted from relevant studies. Risk of bias was evaluated using the Newcastle-Ottawa scale (NOS). Results Our search yielded 85 potential publications. Nineteen full texts were reviewed, and a total of 12 articles were included in this systematic review. There were six retrospective and six prospective cohort studies. The most common DL algorithm used was the Convolutional Neural Network (CNN). Performance comparison was carried out via single modality comparison. The median performance for each best-performing algorithm was an AUC of 0.845 (range 0.71–0.99) and Accuracy of 0.85 (0.83–0.98). Conclusions There is a promising role for DL models in the prediction of pCR following neoadjuvant-CRT for LARC. Further studies are needed to provide a standardised comparison in order to allow for large-scale clinical application. PROPERO Registration PROSPERO 2021 CRD42021269904 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021269904.
- 18 August 2023
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 408 (1) , 1-11
Accuracy of deep neural learning models in the imaging prediction of pathological complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review
Purpose Up to 15–27% of patients achieve pathologic complete response (pCR) following neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). Deep neural learning (DL) algorithms have been suggested to be a useful adjunct to allow accurate prediction of pCR and to identify patients who could potentially avoid surgery. This systematic review aims to interrogate the accuracy of DL algorithms at predicting pCR. Methods Embase (PubMed, MEDLINE) databases and Google Scholar were searched to identify eligible English-language studies, with the search concluding in July 2022. Studies reporting on the accuracy of DL models in predicting pCR were selected for review and information pertaining to study characteristics and diagnostic measures was extracted from relevant studies. Risk of bias was evaluated using the Newcastle-Ottawa scale (NOS). Results Our search yielded 85 potential publications. Nineteen full texts were reviewed, and a total of 12 articles were included in this systematic review. There were six retrospective and six prospective cohort studies. The most common DL algorithm used was the Convolutional Neural Network (CNN). Performance comparison was carried out via single modality comparison. The median performance for each best-performing algorithm was an AUC of 0.845 (range 0.71–0.99) and Accuracy of 0.85 (0.83–0.98). Conclusions There is a promising role for DL models in the prediction of pCR following neoadjuvant-CRT for LARC. Further studies are needed to provide a standardised comparison in order to allow for large-scale clinical application. PROPERO Registration PROSPERO 2021 CRD42021269904 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021269904.
- 19 January 2023
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 19 (6) , 596-605
The management of clinically suspicious para‐aortic lymph node metastasis in colorectal cancer: A systematic review
Approximately 1%–2% of patients with colorectal cancer (CRC) develop para‐aortic lymph node (PALN) metastases, which are typically considered markers of systemic disease, and are associated with a poor prognosis. The utility of PALN dissection (PALND) in patients with CRC is of ongoing debate and only small‐scale retrospective studies have been published on this topic to date. This systematic review aimed to determine the utility of resecting PALN metastases with the primary outcome measure being the difference in survival outcomes following either surgical resection or non‐resection of these metastases. A comprehensive systematic search was undertaken to identify all English‐language papers on PALND in the PubMed, Medline, and Google Scholar databases. The search results identified a total of 12 eligible studies for analysis. All studies were either retrospective cohort studies or case series. In this systematic review, PALND was found to be associated with a survival benefit when compared to non‐resection. Metachronous PALND was found to be associated with better overall survival as compared to synchronous PALND, and the number of PALN metastases (2 or fewer) and a pre‐operative carcinoembryonic antigen level of <5 was found to be associated with a better prognosis. No PALND‐specific complications were identified in this review. A large‐scale prospective study needs to be conducted to definitively determine the utility of PALND. For the present, PALND should be considered within a multidisciplinary approach for patients with CRC, in conjunction with already established treatment regimens.
- 19 January 2023
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 19 (6) , 596-605
The management of clinically suspicious para‐aortic lymph node metastasis in colorectal cancer: A systematic review
Approximately 1%–2% of patients with colorectal cancer (CRC) develop para‐aortic lymph node (PALN) metastases, which are typically considered markers of systemic disease, and are associated with a poor prognosis. The utility of PALN dissection (PALND) in patients with CRC is of ongoing debate and only small‐scale retrospective studies have been published on this topic to date. This systematic review aimed to determine the utility of resecting PALN metastases with the primary outcome measure being the difference in survival outcomes following either surgical resection or non‐resection of these metastases. A comprehensive systematic search was undertaken to identify all English‐language papers on PALND in the PubMed, Medline, and Google Scholar databases. The search results identified a total of 12 eligible studies for analysis. All studies were either retrospective cohort studies or case series. In this systematic review, PALND was found to be associated with a survival benefit when compared to non‐resection. Metachronous PALND was found to be associated with better overall survival as compared to synchronous PALND, and the number of PALN metastases (2 or fewer) and a pre‐operative carcinoembryonic antigen level of <5 was found to be associated with a better prognosis. No PALND‐specific complications were identified in this review. A large‐scale prospective study needs to be conducted to definitively determine the utility of PALND. For the present, PALND should be considered within a multidisciplinary approach for patients with CRC, in conjunction with already established treatment regimens.
- 1 January 2023
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (1-2) , 8-9
Individualized chemotherapy and immunotherapy for rectal cancer: the next step forward
- 1 January 2023
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (1-2) , 8-9
Individualized chemotherapy and immunotherapy for rectal cancer: the next step forward
- 24 December 2022
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 46 (6) , 1169-1176
Surgical challenges of giant parathyroid adenomas weighing 10 g or more
Purpose An average parathyroid adenoma (PA) weighs < 1 g. This study aimed to characterise giant PAs ≥ 10 g (GPAs) to facilitate surgical management of primary hyperparathyroidism (PHPT). Methods All patients with a GPA confirmed on histology were recruited from the Monash University Endocrine Surgery Unit database. Clinical and demographic data were collected and compared to a group of non-GPA patients. Results A total of 14 GPAs were identified between 2007 and 2018 out of 863 patients (1.6%) with a single PA excised for PHPT. The GPA patients were compared to a control group of 849 non-GPA patients in the same period with similar mean age (62 ± 16 vs 63 ± 14, P = 0.66) and gender distribution (64% vs 75% female, P = 0.35). Pre-operative calcium (Ca) and parathyroid hormone (PTH) levels were significantly higher in GPA patients (P < 0.001). A higher percentage of GPA patients (79%) had concordant localisation studies (ultrasound and sestamibi) than control patients (59%), (P = 0.13), but they were significantly less likely to undergo MIP (55% vs 82%, P = 0.02). The median GPA weighed 12.5 g (IQR 10.5–24.3). Median serum Ca normalised by day 1 post-operatively, while PTH remained elevated. Both serum Ca and PTH levels were in the normal range at 3 months. All GPA lesions were benign on histopathology. Conclusion GPAs are rare and display severe clinical and biochemical abnormalities. Despite their large size, concordant pre-operative imaging was not always achieved, and a few patients were suitable for MIP.
- 24 December 2022
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 46 (6) , 1169-1176
Surgical challenges of giant parathyroid adenomas weighing 10 g or more
Purpose An average parathyroid adenoma (PA) weighs < 1 g. This study aimed to characterise giant PAs ≥ 10 g (GPAs) to facilitate surgical management of primary hyperparathyroidism (PHPT). Methods All patients with a GPA confirmed on histology were recruited from the Monash University Endocrine Surgery Unit database. Clinical and demographic data were collected and compared to a group of non-GPA patients. Results A total of 14 GPAs were identified between 2007 and 2018 out of 863 patients (1.6%) with a single PA excised for PHPT. The GPA patients were compared to a control group of 849 non-GPA patients in the same period with similar mean age (62 ± 16 vs 63 ± 14, P = 0.66) and gender distribution (64% vs 75% female, P = 0.35). Pre-operative calcium (Ca) and parathyroid hormone (PTH) levels were significantly higher in GPA patients (P < 0.001). A higher percentage of GPA patients (79%) had concordant localisation studies (ultrasound and sestamibi) than control patients (59%), (P = 0.13), but they were significantly less likely to undergo MIP (55% vs 82%, P = 0.02). The median GPA weighed 12.5 g (IQR 10.5–24.3). Median serum Ca normalised by day 1 post-operatively, while PTH remained elevated. Both serum Ca and PTH levels were in the normal range at 3 months. All GPA lesions were benign on histopathology. Conclusion GPAs are rare and display severe clinical and biochemical abnormalities. Despite their large size, concordant pre-operative imaging was not always achieved, and a few patients were suitable for MIP.
- 20 December 2022
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 95 (5) , 56-64
Anastomotic Leak in Colorectal Surgery: Predictive Factors and Survival
Introduction: Anastomotic leak (AL) is a serious complication following colorectal surgery. Aim: The aim of this study was to identify factors associated with the development of AL and to analyze its impact on survival. Materials and methods: All consecutive adult colorectal cancer resections performed between 2007 and 2020 with curative intent and anastomosis formation were included from a prospectively maintained database. The primary outcome measure was the rate of AL. The secondary outcome measure was 5-year overall survival (OS). Results: There were 6837 eligible patients. The rate of AL was 2.2% and 4.0% in patients with colon and rectal cancer, respectively. AL was a significant independent predictor of reduced 5-year OS in patients who underwent curative surgery for rectal cancer (odds ratio 2.293, p = 0.009). Emergency surgery (p = 0.015), surgery at a public hospital (p = 0.002), and an open surgical approach (p = 0.021) were all associated with a significantly higher risk of AL in patients with colon cancer, with higher rates of AL noted in left colectomies as compared to right hemicolectomies (4.4% vs. 1.3%, p < 0.001). In rectal cancer patients,AL was associated with neoadjuvant chemoradiotherapy (p = 0.038) and male gender (p = 0.002). The anastomosis formation technique (hand-sewn vs. stapled) did not impact the rate of AL (p = 0.116 and p = 0.198 with colon and rectal cancer, respectively). Discussion: Clinicians should be cognizant of the predictive factors for AL and should consider early intervention for at-risk patients.
- 20 December 2022
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 95 (5) , 56-64
Anastomotic Leak in Colorectal Surgery: Predictive Factors and Survival
Introduction: Anastomotic leak (AL) is a serious complication following colorectal surgery. Aim: The aim of this study was to identify factors associated with the development of AL and to analyze its impact on survival. Materials and methods: All consecutive adult colorectal cancer resections performed between 2007 and 2020 with curative intent and anastomosis formation were included from a prospectively maintained database. The primary outcome measure was the rate of AL. The secondary outcome measure was 5-year overall survival (OS). Results: There were 6837 eligible patients. The rate of AL was 2.2% and 4.0% in patients with colon and rectal cancer, respectively. AL was a significant independent predictor of reduced 5-year OS in patients who underwent curative surgery for rectal cancer (odds ratio 2.293, p = 0.009). Emergency surgery (p = 0.015), surgery at a public hospital (p = 0.002), and an open surgical approach (p = 0.021) were all associated with a significantly higher risk of AL in patients with colon cancer, with higher rates of AL noted in left colectomies as compared to right hemicolectomies (4.4% vs. 1.3%, p < 0.001). In rectal cancer patients,AL was associated with neoadjuvant chemoradiotherapy (p = 0.038) and male gender (p = 0.002). The anastomosis formation technique (hand-sewn vs. stapled) did not impact the rate of AL (p = 0.116 and p = 0.198 with colon and rectal cancer, respectively). Discussion: Clinicians should be cognizant of the predictive factors for AL and should consider early intervention for at-risk patients.
- 6 October 2022
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (3) , 506-509
The utility of ctDNA in colorectal cancer with peritoneal metastases
Background The development of peritoneal metastases (PM) in patients with colorectal cancer (CRC) connotates a poor prognosis. Circulating tumour (ctDNA) is a promising tumour biomarker in the management CRC. This systematic review aimed to summarize the role of ctDNA in patients with CRC and PM. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, a systematic review of the literature until June 2022 was performed. Studies reporting on the utility of ctDNA in colorectal PM were included. A total of eight eligible studies were identified including a total of 167 patients. Results The findings from this review suggest an evolving role for ctDNA in CRC with PM. ctDNA can be isolated from both plasma and peritoneal fluid, with peritoneal fluid preferred as the liquid biopsy of choice with higher mutation detection rates. Concordance rates between tissue and plasma/peritoneal ctDNA mutation detection can vary, but is generally high. ctDNA has a potential role in monitoring anti-EGFR treatment response and resistance, as well as in predicting future prognosis and recurrence. The detection of ctDNA in plasma of patients with isolated PM is also possibly suggestive of occult systemic disease, and patients exhibiting such ctDNA positivity may benefit from systemic treatment. Limitations to ctDNA mutation detection may include the size of peritoneal lesions, as well as the fact that PM poorly shed ctDNA. Conclusion While these findings are promising, further large-scale studies are needed to better evaluate the utility of ctDNA in this subset of patients.
- 6 October 2022
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (3) , 506-509
The utility of ctDNA in colorectal cancer with peritoneal metastases
Background The development of peritoneal metastases (PM) in patients with colorectal cancer (CRC) connotates a poor prognosis. Circulating tumour (ctDNA) is a promising tumour biomarker in the management CRC. This systematic review aimed to summarize the role of ctDNA in patients with CRC and PM. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, a systematic review of the literature until June 2022 was performed. Studies reporting on the utility of ctDNA in colorectal PM were included. A total of eight eligible studies were identified including a total of 167 patients. Results The findings from this review suggest an evolving role for ctDNA in CRC with PM. ctDNA can be isolated from both plasma and peritoneal fluid, with peritoneal fluid preferred as the liquid biopsy of choice with higher mutation detection rates. Concordance rates between tissue and plasma/peritoneal ctDNA mutation detection can vary, but is generally high. ctDNA has a potential role in monitoring anti-EGFR treatment response and resistance, as well as in predicting future prognosis and recurrence. The detection of ctDNA in plasma of patients with isolated PM is also possibly suggestive of occult systemic disease, and patients exhibiting such ctDNA positivity may benefit from systemic treatment. Limitations to ctDNA mutation detection may include the size of peritoneal lesions, as well as the fact that PM poorly shed ctDNA. Conclusion While these findings are promising, further large-scale studies are needed to better evaluate the utility of ctDNA in this subset of patients.